Page 59 - Read Online

13. Jaiswal M, LaRusso NF, Gores GJ. Nitric oxide in history. Ann Surg Oncol 2012;19:4238-43.
gastrointestinal epithelial cell carcinogenesis: linking 31. Brooks PJ, Enoch MA, Goldman D, Li TK, Yokoyama A.
infl ammation to oncogenesis. Am J Physiol Gastrointest Liver The alcohol fl ushing response: an unrecognized risk factor
Physiol 2001;281:G626-34. for esophageal cancer from alcohol consumption. PLoS Med
14. Porta C, Riboldi E, Sica A. Mechanisms linking 2009;6:50.
pathogens-associated infl ammation and cancer. Cancer Lett 32. Yoshida A, Huang IY, Ikawa M. Molecular abnormality of an
2011;305:250-62. inactive aldehyde dehydrogenase variant commonly found in
15. Wu WK, Sung JJ, Lee CW, Yu J, Cho CH. Cyclooxygenase-2 Orientals. Proc Natl Acad Sci U S A 1984;81:258-61.
in tumorigenesis of gastrointestinal cancers: an update on the 33. Islami F, Boffetta P, Ren JS, Pedoeim L, Khatib D, Kamangar F.
molecular mechanisms. Cancer Lett 2010;295:7-16. High-temperature beverages and foods and esophageal cancer
16. Williams CS, Mann M, DuBois RN. The role of risk-a systematic review. Int J Cancer 2009;125:491-524.
cyclooxygenases in infl ammation, cancer, and development. 34. Hardefeldt HA, Cox MR, Eslick GD. Association between
Oncogene 1999;18:7908-16. human papillomavirus (HPV) and oesophageal squamous cell
17. Liao X, Lochhead P, Nishihara R, Morikawa T, Kuchiba A, carcinoma: a meta-analysis. Epidemiol Infect 2014;142:1119-37.
Yamauchi M, Imamura Y, Qian ZR, Baba Y, Shima K, 35. Rustgi AK, El-Serag HB. Esophageal carcinoma. N Engl J
Sun R, Nosho K, Meyerhardt JA, Giovannucci E, Fuchs CS, Med 2014;371:2499-509.
Chan AT, Ogino S. Aspirin use, tumor PIK3CA mutation, and 36. Cameron AJ, Ott BJ, Payne WS. The incidence of
colorectal-cancer survival. N Engl J Med 2012;367:1596-606. adenocarcinoma in columnar-lined (Barrett’s) esophagus.
18. Din FV, Theodoratou E, Farrington SM, Tenesa A, N Engl J Med 1985;313:857-9.
Barnetson RA, Cetnarskyj R, Stark L, Porteous ME, 37. Shaheen NJ, Richter JE. Barrett’s oesophagus. Lancet
Campbell H, Dunlop MG. Effect of aspirin and NSAIDs on 2009;373:850-61.
risk and survival from colorectal cancer. Gut 2010;59:1670-9.
19. Karin M, Greten FR. NF-kappaB: linking infl ammation 38. Polk DB, Peek RM Jr. Helicobacter pylori: gastric cancer and
beyond. Nat Rev Cancer 2010;10:403-14.
and immunity to cancer development and progression.
Nat Rev Immunol 2005;5:749-59. 39. De Martel C, Ferlay J, Franceschi S, Vignat J, Bray F,
20. Chen LW, Egan L, Li ZW, Greten FR, Kagnoff MF, Karin M. Forman D, Plummer M. Global burden of cancers attributable
to infections in 2008: a review and synthetic analysis.
The two faces of IKK and NF-kappaB inhibition: prevention Lancet Oncol 2012;13:607-15.
of systemic infl ammation but increased local injury following
intestinal ischemia-reperfusion. Nat Med 2003;9:575-81. 40. Blaser MJ, Perez-Perez GI, Kleanthous H, Cover TL,
21. Karin M. Nuclear factor-kappaB in cancer development and Peek RM, Chyou PH, Stemmermann GN, Nomura A. Infection
with Helicobacter pylori strains possessing cagA is associated
progression. Nature 2006;441:431-6.
22. Soutto M, Belkhiri A, Piazuelo MB, Schneider BG, Peng D, with an increased risk of developing adenocarcinoma of the
stomach. Cancer Res 1995;55:2111-5.
Jiang A, Washington MK, Kokoye Y, Crowe SE, Zaika A,
Correa P, Peek RM Jr, El-Rifai W. Loss of TFF1 is associated 41. Higashi H, Tsutsumi R, Muto S, Sugiyama T, Azuma T,
with activation of NF-kappaB-mediated infl ammation and gastric Asaka M, Hatakeyama M. SHP-2 tyrosine phosphatase as
neoplasia in mice and humans. J Clin Invest 2011;121:1753-67. an intracellular target of Helicobacter pylori CagA protein.
23. Barnes PJ, Karin M. Nuclear factor-kappaB: a pivotal Science 2002;295:683-6.
transcription factor in chronic infl ammatory diseases. 42. Saadat I, Higashi H, Obuse C, Umeda M, Murata-Kamiya N,
N Engl J Med 1997;336:1066-71. Saito Y, Lu H, Ohnishi N, Azuma T, Suzuki A, Ohno S,
24. Karin M. NF-kappaB and cancer: mechanisms and targets. Hatakeyama M. Helicobacter pylori CagA targets
PAR1/MARK kinase to disrupt epithelial cell polarity. Nature
Mol Carcinog 2006;45:355-61. 2007;447:330-3.
25. Huo X, Juergens S, Zhang X, Rezaei D, Yu C, Strauch ED, 43. Brandt S, Kwok T, Hartig R, König W, Backert S. NF-kappaB
Wang JY, Cheng E, Meyer F, Wang DH, Zhang Q, Spechler SJ, activation and potentiation of proinfl ammatory responses by the
Souza RF. Deoxycholic acid causes DNA damage while
inducing apoptotic resistance through NF-kappaB activation Helicobacter pylori CagA protein. Proc Natl Acad Sci U S A
in benign Barrett’s epithelial cells. Am J Physiol Gastrointest 2005;102:9300-5.
Liver Physiol 2011;301:G278-86. 44. Xiong H, Du W, Sun TT, Lin YW, Wang JL, Hong J,
26. Naugler WE, Karin M. NF-kappaB and cancer-identifying Fang JY. A positive feedback loop between STAT3 and
targets and mechanisms. Curr Opin Genet Dev 2008;18:19-26. cyclooxygenase-2 gene may contribute to Helicobacter
27. Baan R, Straif K, Grosse Y, Secretan B, El Ghissassi F, pylori-associated human gastric tumorigenesis. Int J Cancer
2014;134:2030-40.
Bouvard V, Altieri A, Cogliano V; WHO International Agency for
Research on Cancer Monograph Working Group. Carcinogenicity 45. Fenoglio-Preiser CM, Wang J, Stemmermann GN,
of alcoholic beverages. Lancet Oncol 2007;8:292-3. Noffsinger A. TP53 and gastric carcinoma: a review. Hum
28. Morita M, Saeki H, Mori M, Kuwano H, Sugimachi K. Risk Mutat 2003;21:258-70.
factors for esophageal cancer and the multiple occurrence 46. Stock M, Otto F. Gene deregulation in gastric cancer. Gene
of carcinoma in the upper aerodigestive tract. Surgery 2005;360:1-19.
2002;131:1-6. 47. Morgan C, Jenkins GJ, Ashton T, Griffi ths AP, Baxter JN,
29. Oka D, Yamashita S, Tomioka T, Nakanishi Y, Kato H, Parry EM, Parry JM. Detection of p53 mutations in
Kaminishi M, Ushijima T. The presence of aberrant DNA precancerous gastric tissue. Br J Cancer 2003;89:1314-9.
methylation in noncancerous esophageal mucosae in association 48. Honjo T, Kinoshita K, Muramatsu M. Molecular mechanism
with smoking history: a target for risk diagnosis and prevention of class switch recombination: linkage with somatic
of esophageal cancers. Cancer 2009;115:3412-26. hypermutation. Annu Rev Immunol 2002;20:165-96.
30. Shigaki H, Baba Y, Watanabe M, Iwagami S, Miyake K, 49. Cascalho M. Advantages and disadvantages of cytidine
Ishimoto T, Iwatsuki M, Baba H. LINE-1 hypomethylation in deamination. J Immunol 2004;172:6513-8.
noncancerous esophageal mucosae is associated with smoking 50. Kinoshita K, Nonaka T. The dark side of activation-induced

142 Journal of Cancer Metastasis and Treatment ¦ Volume 1 ¦ Issue 3 ¦ October 15, 2015 ¦